Theodoros Xanthos, Panagiotis V.S. Vasileiou, Sotirios Kakavas, Aggeliki Syggelou and Nicoletta Iacovidou Pages 1517 - 1529 ( 13 )
Sudden cardiac arrest is a leading cause of death worldwide with survival rates still remaining suboptimal. Unfortunately, most cardiac arrest patients, who achieve return of spontaneous circulation (ROSC), develop a multi-faceted post-cardiac arrest syndrome, including post-cardiac arrest brain injury, myocardial dysfunction, and systemic ischemia/reperfusion response.
Erythropoietin (EPO), the principal hematopoietic hormone regulating erythropoiesis, exhibits diverse cellular effects in nonhematopoietic tissues. Due to its anti-apoptotic, anti-inflammatory, and anti-oxidant properties, as well as its angiogenic action, EPO plays a role in neuroprotection and cardioprotection. In this regard, EPO represents a promising agent in the cardiac arrest setting, based on a therapeutic strategy that focuses on the post-resuscitation phase.
This review aims to provide a comprehensive account of EPOs role in the treatment of each individual component of post-cardiac arrest syndrome.
Erythropoietin,Cardiac arrest,Post-cardiac arrest syndrome,Neuroprotection,Cardioprotection,Anti-oxidant,hematopoietic,heterotrimer,dysfunction,reperfusion,homeostasis,cardiopulmonary,leukocytes,apoptotic,P-selectin,astrocytes,hypoxic,necrosis
, , , , Department of Anatomy, University of Athens, Medical School, P.O. Box 11527, 75 M.Asias, Goudi, Athens, Greece.